High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

Part of paid clinical trials in Fort Collins, Colorado.

Sponsor
Eye Center of Northern Colorado, P.C.
Study ID
NCT01205035
Phase
PHASE2
Status
Completed

Conditions

  • Retinal Diseases
  • Telangiectasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab 2.0mg — DRUG
    Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections

Study Details

Idiopathic Parafoveal Telangiectasia (IPT) \[also known as Idiopathic Perifoveal Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia (MacTel)\] is a disorder of unknown etiology. IPT is classified as Group 2A in the Gass classification of macular telangiectasias (Reference 1,5) - a bilateral, but not always symmetric disorder. It is characterized in its early stages by dilation and loss of parafoveal capillaries accompanied by angiographic leakage, "right angle" venules, central and parafoveal intraretinal cysts.

Key Dates

First listed
Sep 20, 2010
Start date
Oct 31, 2010
Status verified
Mar 2015
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
6 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Observation
    Observation; No treatment given
  • Experimental: Intravitreal ranibizumab 2.0mg
    Initial dose 2.0mg switched to 1.0mg at near conclusion of study.

Primary Outcome Measure

Visual Acuity Change From Baseline to Month 12 of the Study [ Time Frame: Baseline to 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Eye Center of Northern ColoradoFort CollinsColorado80525-

Find similar trials in Fort Collins, CO

By research site
Eye Center of Northern Colorado· Fort Collins, CO

Related Studies